Clinical trials: Finerenone
Heart Failure
Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets
This study should estimate the dose proportionality of BAY94-8862 IR tablets.
- Trial name
- NCT01687920
- Testing
- BAY94-8862 (1.25mg), BAY94-8862 (2.5mg), BAY94-8862 (5mg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Clinical Pharmacology
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.
- Trial name
- NCT01473108
- Testing
- Finerenone (BAY 94-8862) PEG solution, Finerenone (BAY 94-8862) immediate release tablet, Eplerenone (Inspra®)
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
In this bioequivalence study, healthy male participants took the study treatment finerenone in the form of one and two tablets of different strengths by mouth.
- Trial name
- NCT07116512
- Testing
- Finerenone (BAY94-8862): intervention A, Finerenone (BAY94-8862): intervention B
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Pharmacokinetics
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg…
- Trial name
- NCT02956109
- Testing
- Finerenone (BAY94-8862): 1 0mg tablet, Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets, Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Pharmacokinetics
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a novel liquid formulation for the…
- Trial name
- NCT02957396
- Testing
- Finerenone (BAY94-8862): 20 mg intact tablet, Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet, Finerenone (BAY94-8862): 20 mg suspension
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Worsening Chronic Heart Failure, Chronic Kidney Disease
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should.
- Trial name
- NCT04908436
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer